BioMarin Pharma (BMRN) Tops Q2 EPS by 31c, Offers Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. JNJ
2. OIG
3. NRIX
4. SUNS
5. META
6. ACI
7. SPY
8. SNDX
9. HUM
10. S

Go back to BioMarin Pharma (BMRN) Tops Q2 EPS by 31c, Offers Guidance

BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date

July 31, 2023 4:03 PM EDT

VOXZOGO® Growth Continued in the Second Quarter Driven by Global Demand Resulting in Increased Full Year 2023 GuidancePivotal Program with VOXZOGO in New, Potential Second Indication, Hypochondroplasia, to Begin in the Fourth Quarter of 2023U.S. Approval of ROCTAVIAN Received in the Second Quarter and Commercial Launch Underway; Commercial Launch in Europe Making Progress

Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)



Three Months Ended

June... More